Scarica l'app Stockscreener
49.60
6.04%
-3.19
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Travere Therapeutics Inc Borsa (TVTX) Ultime notizie
An officer proposes selling 243,735 shares at Travere Therapeutics (TVTX). - Stock Titan
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Travere therapeutics chief research officer William Rote sells $13.1m in stock - Investing.com Nigeria
Travere Therapeutics CLO Elizabeth Reed sells $2.34m in stock By Investing.com - Investing.com Nigeria
Travere Therapeutics EVP Peter Heerma sells $17.8m in company stock - Investing.com
Travere Therapeutics CFO Cline sells $3.1m in company stock - Investing.com
Travere Therapeutics SVP sells $335k in stock - Investing.com
Travere Therapeutics SVP sells $335k in stock By Investing.com - Investing.com Canada
Travere (TVTX) R&D boss sells stock under 10b5-1 plan—how big was the trade? - Stock Titan
Insider at Travere (NASDAQ: TVTX) sells stock under preset trading plan - Stock Titan
Travere Therapeutics (TVTX) legal chief sells 37,500 shares under trading plan - Stock Titan
Travere CFO (NASDAQ: TVTX) sells 50K shares in pre-set trading plan - Stock Titan
Travere Therapeutics (TVTX) CEO trades 400K shares under preset plan - Stock Titan
Travere Therapeutics (TVTX) research chief unloads shares under a preset plan, with the sale size now disclosed - Stock Titan
Planned $6.9M stock sale in Travere (NASDAQ: TVTX) - Stock Titan
Travere Therapeutics, Inc.Common Stock (Nasdaq:TVTX) Price Chart - The Chronicle-Journal
Travere Therapeutics (TVTX) chief accounting officer sells 5,375 shares under preset plan - Stock Titan
Travere (NASDAQ: TVTX) insider plans more stock sales after multi-million plan trades - Stock Titan
Travere Therapeutics CFO Cline sells $3.1m in company stock By Investing.com - Investing.com Canada
Travere Therapeutics (NASDAQ: TVTX) officer plans 112,850-share sale after recent 96,198-share trade - Stock Titan
After $6M sale, Travere (NASDAQ: TVTX) insider plans another stock move - Stock Titan
Travere Therapeutics (TVTX) insider plans 172,717-share sale after option exercise - Stock Titan
Insider plans 39,576-share sale at Travere Therapeutics (NASDAQ: TVTX) in 2026 - Stock Titan
Travere Therapeutics (NASDAQ: TVTX) shareholder Eric Dube plans 95,666-share sale in September 2026 - Stock Titan
Travere Therapeutics (NASDAQ: TVTX) officer may sell shares after cashing in options - Stock Titan
$2.9M planned stock sale at Travere (NASDAQ: TVTX) comes from equity awards - Stock Titan
Over 100,000 Travere (NASDAQ: TVTX) shares lined up for insider sale - Stock Titan
Travere Therapeutics (NASDAQ: TVTX) officer plans Rule 144 sale of compensation shares - Stock Titan
TVTX Form 4 FilingsTravere Therapeutics, Inc. SEC Form 4 - Stock Titan
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo! Finance Canada
Director at Travere Therapeutics (TVTX) sells 20,000 shares under preset trading plan - Stock Titan
Show Me The Money: Filspari Powers Travere Therapeutics' Growth - RTTNews
Travere Therapeutics grants inducement RSUs covering 56,220 shares to 16 new employees - Bitget
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Travere Therapeutics stock hits 52-week high at 68.25 USD By Investing.com - Investing.com Australia
Travere Therapeutics (NASDAQ: TVTX) director plans 2026 stock sale - Stock Titan
TVTX: FILSPARI's momentum and pipeline progress position the business for sustained growth - TradingView
Travere Therapeutics at Cantor conference: filspari drives growth By Investing.com - Investing.com Canada
Travere Therapeutics at Cantor conference: filspari drives growth By Investing.com - Investing.com UK
Travere Therapeutics stock hits 52-week high at 68.25 USD By Investing.com - Investing.com Nigeria
Travere Therapeutics stock hits 52-week high at 68.25 USD - investing.com
Travere Therapeutics stock hits 52-week high at 68.25 USD By Investing.com - Investing.com Canada
Travere Therapeutics stock hits 52-week high at 68.25 USD By Investing.com - Investing.com UK
Travere Therapeutics' Outlook Brightens As Turnaround Looms - Investor's Business Daily
FDA issues Untitled Letter to Travere Therapeutics over visual aid for kidney disease drug Filspari - Medical Marketing and Media
Seong Chi: Excited to Join Travere Therapeutics as Director, Scientific Engagement and Professional Societies - Oncodaily
Biotech Stocks At 52-Week HighsATTO, HALO, IKT, TVTX, ATRC - RTTNews
Travere Therapeutics CFO Christopher R. Cline Executes 642-Share Sale for Tax Withholding on RSU Vesting - Kalkine Media
9.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):